While other prostate-cancer-targeting tracers have been studied, such as prostate stem cell antigens, gastrin-releasing peptide receptors, and urokinase plasminogen activators, among many others, PSMA has had the most promising history. This evidence concerns the gene PLAU and prostate cancer.